Drug Approval | August 28, 2021
DCGI approves Enzene biosimilar Denosumab for Osteoporosis
This is Enzene Biosciences third biosimilar to be approved
This is Enzene Biosciences third biosimilar to be approved
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
The company recently raised US $ 2.25 million seed round and the app was CE-Certified as a medical device in Europe
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
It is estimated that 300 million men worldwide were affected by ED in 2020, a figure projected to increase to 322 million by 2025. Nearly 30% of these were aged between 40 and 70
Subscribe To Our Newsletter & Stay Updated
